AN OPEN-LABEL, CROSSOVER STUDY OF ALTERNATIVE DIETARY THERAPIES FOR GLYCOGEN STO

这个子项目是利用由NIH/NCRR资助的中心拨款提供的资源的许多研究子项目之一。子项目和调查员(PI)可能从另一个NIH来源获得了主要资金，因此可能会出现在其他CRISE条目中。列出的机构是针对中心的，而不一定是针对调查员的机构。目的：1.确定三种新的葡萄糖来源的血糖指数低于目前使用的玉米淀粉的效果。假设--与传统的玉米淀粉疗法相比，预计低血糖指数疗法将在更长的时间内将血糖水平维持在70 mg/dL以上。2.确定每种葡萄糖来源的代谢控制。假设？由于新的葡萄糖来源的血糖指数较低，预计它们将提供更好的代谢控制。3.评估每种产品的不良反应情况。假设-据预测，新的葡萄糖来源不会产生比传统的Argo玉米淀粉更大的副作用。有些食物含有不能被人体酶消化的糖，结果可能会被结肠中的细菌消化，产生气体，可能会引起不适。正在探索的三种碳水化合物来源中未消化糖的含量较低，应该会造成最小的不适。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Aims: 1. To determine the efficacy of three new glucose sources that have a lower glycemic index then the currently used cornstarch. Hypothesis - It is expected that the lower glycemic index therapies will maintain a blood sugar level above 70 mg/dL for a greater amount of time than the traditional cornstarch therapy. 2. To determine the metabolic control of each glucose source. Hypothesis ¿ Due to the lower glycemic index of the new glucose sources it is anticipated that they will deliver better metabolic control. 3. To assess the adverse side effect profile of each of the products. Hypothesis - It is projected that the new glucose sources will produce no greater adverse side effects than the traditional Argo cornstarch. Some foods contain sugars that are undigestable by human enzymes and resultantly may be digested by bacteria in the colon which produces gas and may cause discomfort. The three carbohydrate sources being explored are low in undigestable sugars and should cause minimal discomfort.